First Tracks Biotherapeutics is trading at $48.76, up 5.22%, after positive ANB033 celiac-trial results.
- The company reported a narrower third-quarter net loss of $31.4 million and pro forma cash of $343 million after its October financing; it plans late-stage development in 2027.
- Guggenheim raised its price target to $110 from $100, adding a company-specific catalyst. The biotech sector’s 2.13% gain may also have supported shares, but company news is the stronger explanation.